OTS - LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches
2023. December 06. 16:00
Andernach, 6 December, 2023 (APA/OTS) - LTS, a leading
pharmaceutical technology company, announced today that it has
received a grant from the Bill & Melinda Gates Foundation. The
grant will support new formulation methods for mRNA, such as
dissolvable microneedle array patches (MAPs), to increase the
thermostability of the overall product for its use in low- and
middle-income countries (LMICs), especially in hard-to-reach
conditions. This grant will fund $1.2 million over a duration of 15
months.
mRNA technology is considered a potential game-changer for a
range of infectious diseases, including tuberculosis, malaria, and
Lassa fever, which disproportionately affect people in LMICs. One
of the major challenges the world faces in getting these
life-saving vaccines to vulnerable populations - particularly those
in poorer countries - is the need to store them at very low
temperatures. The need for frozen storage of the current generation
of mRNA vaccines is due to the fragility of mRNA molecules. The
incorporation of mRNA into a dissolvable MAP may overcome this
challenge by protecting the mRNA against degradation, removing the
need for frozen storage, and simplifying the access to people
living in LMICs.
At the World Vaccine Congress in Barcelona, LTS recently
presented pre-clinical data from an mRNA/LNP MAP-based vaccination
against rabies, from a collaboration with a biopharmaceutical
company. This successful pre-clinical study with mRNA/LNP vaccine
against rabies demonstrated that the cold-chain requirements can be
reduced from -80?C to 2-8?C by using a MAP instead of an injectable
formulation.
MAPs are an innovative drug delivery technology that offers
advantages in comparison to established drug delivery applications,
such as the opportunity for dose-sparing, lowering requirements for
cold-chain and the possibility for self-administration.
Bas van Buijtenen, CEO of LTS, commented: "At LTS, we care
passionately about bringing patient friendly drug delivery to
people worldwide. We are honoured to be receiving support from the
Gates Foundation in creating solutions for populations that would
otherwise be at risk of being left behind. With MAPs, we aim to
deliver improved access to essential vaccines to these groups,
potentially saving lives."
"The LTS MAP team is excited to have support from the Gates
Foundation for the development of a thermostable mRNA/LNP MAP",
said Dr. Frank Theobald, Head of MAP Program at LTS. "LTS has made
great progress recently with its MAP Program with respect to
pre-clinical and clinical data, taking steps towards the up-scaling
and commercialization of the MAP technology. LTS believes that MAPs
will be a breakthrough technology for improving vaccination
coverage in LMICs. Support from the foundation will help to develop
the MAP technology further and bring it to the next level of
maturity and make it accessible for patients in the foreseeable
future."
Picture is available at AP -
https://apmultimedianewsroom.com/multimedia-newsroom/partners/news-aktuell
About LTS
We CARE. We CREATE. We DELIVER. The driving philosophy behind
LTS. As a trusted technology partner for the pharmaceutical
industry, we develop and manufacture innovative drug delivery
systems such as Transdermal Patches ("TTS") and Oral Thin Films
("OTF") as well as wearable drug delivery devices ("OBDS"). LTS´
commercial offering encompasses more than 20 marketed products and
a diverse pipeline of more than 40 development projects targeting
multiple disease indications. LTS's innovation pipeline contains
both partner-funded as well as proprietary, LTS-funded projects.
LTS maintains its leading position through the continuous
refinement of its core TTS and OTF technologies and by advancing
emerging drug delivery technologies, including Microneedle Array
Patches ("MAP") for the transdermal delivery of small and large
molecules, biological actives and vaccines. With its SorrelTM
wearable drug delivery platform LTS offers patient friendly
solutions for complex drugs delivery at home. Founded in 1984, LTS
operates today from four sites: in Andernach, Germany, West
Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has
also a representative office in Shanghai, China.
Contact
Dr Iris Schnitzler
iris.schnitzler@ltslohmann.com
+49 2632 992589
LTS LOHMANN Therapy Systems AG
Lohmannstrasse 2
56626 Andernach
Germany
Phone: +49 (0) 2632 99-0
Fax: +49 (0) 2632 99-22 00
info@ltslohmann.com
www.ltslohmann.com
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.